Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Authors' conclusion
Naltrexone/bupropion did not demonstrate effectiveness for reducing binge eating relative to placebo but showed effectiveness for weight reduction in patients with BED. Obesity status did not predict or moderate medication outcomes.
Study context
- Population
- Patients with binge-eating disorder (BED) with and without obesity (70.8% women, 69.7% White, mean age 45.7 y, mean BMI 35.1 kg/m², 77.5% with BMI ≥30 kg/m²)92.1% completed post-treatment assessments
- Participants
- 89 patients
- Comparison
- Naltrexone/bupropion vs placebo
- Naltrexone/bupropionn = 43
- Placebon = 46reference
Methodological detailsdouble-blind, placebo-controlled, 12-week, randomization stratified by obesity status and gender
- Double-blind
- Placebo-controlled
- 12-week
- Randomization stratified by obesity status and gender
Primary result
As reported in the abstract
Binge-eating frequency · 12 weeks
- Significant reductions in binge-eating frequency that did not differ significantly between naltrexone/bupropion and placebo
- Binge-eating remission rates did not differ significantly between naltrexone/bupropion and placebo
Further findings
Attaining ≥5% weight loss
Percentage weight loss
- Naltrexone/bupropion associated with significantly greater percentage weight loss than placebo
Attaining ≥5% weight loss
- Significantly higher rate with naltrexone/bupropion than placebo
Obesity status as predictor or moderator
- Obesity status did not predict or moderate binge-eating or weight-loss outcomes
Original publication
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity (Silver Spring). Published 26 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →